CinRx Pharma

CinRx Pharma

CinRx Pharma was established in 2015 by Dr. Jon Isaacsohn, a Harvard-trained cardiologist and former Chief Medical Officer of Teva Pharmaceuticals, alongside Dr. August Troendle, the founder and CEO of the global CRO Medpace. The firm operates out of Medpace’s headquarters in Cincinnati, and its leadership bench is heavily stocked with former Medpace scientists and drug developers. CinRx deploys capital and in-house expertise across a portfolio of wholly owned or controlled subsidiary companies — each called a CinCo — that advance a single therapeutic candidate through clinical development. The model covers a range of asset classes including small and large molecules, with programs spanning cardiology, gastrointestinal disorders, and metabolic disease. Confirmed portfolio entities include CinCor Pharma (sold to AstraZeneca for $1.8bn in early 2023, per AstraZeneca, 2023) and CinDome, CinSano, and CinFina. The firm draws on a strategic CRO partnership with Medpace for clinical execution and relies on a centralized team of toxicologists, pharmacologists, and regulatory specialists to govern each CinCo’s development path. The footprint is domestic, with programs run out of Cincinnati and clinical sites across the United States. The firm employs a lean team of roughly 17 professionals named on its website, including a Chief Medical Officer, Chief Translational Science Officer, and dedicated directors for CMC, toxicology, and portfolio management. Adjacent structures include the founding relationship with Medpace, whose CEO chairs CinRx’s board. In February 2023, the portfolio company CinCor Pharma was acquired by AstraZeneca, a transaction that validated the CinCo build-and-partner model. CinRx’s architecture flips the conventional biotech startup model: instead of each portfolio company building its own operating infrastructure, CinRx provides a shared-services backbone — clinical monitoring, CMC, regulatory, and finance — across all CinCos. This structure allows an individual asset to advance through clinical gates without having to assemble a full company around it, a pattern that mirrors how contract research organizations deploy resources but applied as an in-house asset-creation engine.